Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pfizer may have to pay more cash and top $105 bln to win AstraZeneca

Tue, 29th Apr 2014 13:59

* Initial 30 pct cash component too low for AZ investors

* Pfizer may give more cash but limited by UK domicile move

* "White knights" thin on ground, Amgen said not interested

By Ben Hirschler and Simon Jessop

LONDON, April 29 (Reuters) - U.S. drugmaker Pfizer will need to raise its bid for AstraZeneca to around$105-110 billion and increase the proportion of cash in theoffer to win its British rival, investors believe.

After showing his hand and pressuring his smaller competitoron Monday by disclosing two bid approaches, both of which wererebuffed, Pfizer CEO Ian Read has until May 26 to "put up orshut up" under UK takeover rules.

Importantly, after a jump in Pfizer shares, Read knows hehas the backing of many of his own shareholders, while thethreat of a counterbid does not appear imminent.

Read and his team will be using the time available toconsider how they can sweeten an offer made in January worth58.8 billion pounds ($98.8 billion), or 46.61 pounds a share,comprising 30 percent cash and 70 percent shares.

AstraZeneca said that offer fell "very significantly" shortand it specifically flagged the small cash component, whichwould leave investors exposed to the risks faced by Pfizer inexecuting an ambitious mega-merger.

So far, the British group has refused to talk to Pfizer -but it has not ruled out discussions altogether and one personclose to the company said the cash component of any fresh offerwould be key in determining if there was engagement in future.

Cash is uppermost in the minds of AstraZeneca shareholders,too.

"For it to move forward from here, they (Pfizer) need tofind a way of getting Astra management engaged and that feelslike it needs a specific value being applied to the group, andit needs the cash element to be higher," said Alastair Gunn ofJupiter Fund Management, which is a top-20 investor inAstraZeneca.

Analysts at Jefferies believe a deal could get done withPfizer offering a 50/50 split between cash and shares at a priceof at least 50 pounds a share.

Several investors contacted by Reuters confirmed they werelooking for 50 pounds a share or more, with Neil Veitch of SVMAsset Management predicting an agreed deal somewhere between 52and 53 pounds.

Because a key goal of the planned takeover is to get the taxadvantages of re-domiciling the enlarged group in Britain, thereis a limit to how much cash Pfizer can offer, since at least 20percent of its shareholders are required to be UK-based.

"We estimate Pfizer will need to issue a minimum of around$55 billion in shares to comfortably meet this requirement,"Jefferies said.

Based on the original 30 percent cash element, Moody'sanalyst Michael Levesque said Pfizer could fund the whole of thecash portion with offshore funds.

Pushing the cash element to 50 percent, however, wouldrequire taking on some incremental debt.

SORIOT CANVASSES INVESTORS

AstraZeneca CEO Pascal Soriot, whose efforts to revive thefirm's drug pipeline have proved a key draw for Pfizer, will nowbe canvassing the views of shareholders as a "priority", withmachinery in place for meetings with big and small investors,two people close to the company said.

Soriot and chairman Leif Johansson will also be weighingstrategic alternatives for the drugmaker, including thepotential spin-off of non-core therapy areas like infection andneuroscience, as well as possible acquisitions.

But "white knight" counterbidders ready to take on Pfizerare likely to be thin on the ground - not least because fewother companies would enjoy the same cost and tax benefits fromacquiring AstraZeneca as Pfizer.

Amgen is one player for whom an AstraZeneca dealmight make sense, since the two companies are co-developing anumber of drugs, but a person familiar with the U.S. biotechfirm said on Tuesday it was not interested in entering the fray.

French drugmaker Sanofi is another company withthe heft and M&A experience to consider intervening, yet its CEOChris Viehbacher said on Tuesday he planned to stick to smallerbolt-on acquisitions.

GlaxoSmithKline, the British company with arguablythe greatest potential to extract synergies from buyingAstraZeneca, has meanwhile said for several years it is notinterested in large deals.

($1 = 0.5950 British Pounds) (Additional reporting by Anjuli Davies; Editing by Mark Potter)

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.